Skip to main content

Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry

Palm Beach, FL – April 22, 2021 – There are more than 600 types of neuro-disorders affecting the brain, spine, or nerves. Although some prevalent disorders such as cerebral stroke, Alzheimer’s disease, Parkinson’s disease, brain tumors, and epilepsy, are well-studied, most neurological disorders are complicated and rare requiring further in-depth knowledge about the underlining pathophysiology. A report from Grand View Research recently said that the global neurological biomarkers market size was estimated at USD 5,564.8 million in 2018 and is expected to exhibit a CAGR of 14.5% during the forecast period. (2021-2028) Rising prevalence of neurological diseases and increasing emphasis on early diagnosis & treatment are expected to drive the market growth. Another report from Fortune Business Insight went even a little further saying that the global central nervous system treatment market size was USD 81.67 billion in 2020. The global impact of COVID-19 has been unprecedented and staggering, with the central nervous system treatment witnessing a negative demand shock across all regions amid the pandemic. Based on our analysis, the market exhibited a healthy growth of 9.4% in 2020. The market is expected to grow from USD 89.02 billion in 2021 to USD 166.53 billion in 2028 at a CAGR of 9.4% in the 2021-2028 period. The sudden increase in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.   Active healthcare stocks in the markets this week include Senseonics Holdings, Inc. (NYSE: SENS), Global WholeHealth Partners Corp (OTCPK: GWHP), Neurocrine Biosciences, Inc. (NASDAQ: NBIX), Asensus Surgical, Inc. (NYSE: ASXC), Abbott (NYSE: ABT).


Grand View added that: “High prevalence of neurological disorders is a key driver for this market. As per the WHO estimates published in 2018, over 300 million people of all ages suffer from clinical depression, worldwide. Furthermore, lack of efficient diagnostics in developing and undeveloped countries may enhance the mortality rate of neurological disorders.”  Fortune concluded: “The central nervous system (CNS) treatment market is projected to expand at an incredible growth rate. Over the past years, the world has witnessed a striking increase in neurological disorders’ diagnosis rate. According to The Parkinson’s Foundation, around 60,000 individuals from America are diagnosed with Parkinson’s disease. Additionally, over 1 million patients seek treatment for the disease in the country. This rise in chronic neurological illness will considerably stimulate market growth. Combined with this, the industry is also expected to witness new product launches resulting in increased access to various patient groups globally. Furthermore, the challenges faced in developing therapeutics for central nervous system disorders have engaged researchers and developers to innovate new drugs into the market.


Global WholeHealth Partners Corp (OTC Pink: GWHP) BREAKING NEWS:  Global WholeHealth Partners Corp Partners with Nunzia Pharmaceutical Inc., Opening New Global Avenues of Revenue and Products – Global WholeHealth Partners Corp, a multinational supplier of over 70+ FDA Approved Diagnostic Tests attains breakthrough on rising neurological disease.


“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders.” said Mr. Strongo. “Nunzia Pharmaceutical with a nutraceutical for anxiety and stress based on their patented formulas and there pharmaceutical drug there are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests”, say Mr. Strongo.


The marketing and sales partnership Nunzia Pharmaceutical with 8k filing dated 04/19/2021, gives Global the ability to sell the AstraZeneca Vaccine and the Johnson & Johnson vaccine and other products of Nunzia including their patented nutraceutical for stress and anxiety and soon FDA approved drug for ASD (Autistic Spectrum of Disorders), including Autism, ADD, ADHD, Fragile X, and PTSD. The Nunzia Nutraceutical aids in Nutritional deficiencies and therefore helps people.


Nutritional deficiencies. Not drinking enough liquids (dehydration); not getting enough thiamin (vitamin B-1), which is common in people with chronic alcoholism; and not getting enough vitamins B-6 and B-12 in your diet can cause dementia-like symptoms. Copper and vitamin E deficiencies also can cause dementia symptoms.


Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, “The Company’s goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.”  CONTINUED…    Read this entire release for the Global WholeHealth news at:


Other recent news and developments in the healthcare industry include:


Senseonics Holdings, Inc. (NYSE American: SENS) recently reported financial results for the quarter and full year ended December 31, 2020.


Recent Highlights & Accomplishments: Generated fourth quarter 2020 revenue of $3.9 million primarily driven by orders to support the European installed base up to the Ascensia Diabetes Care commercial transition; Raised $175 million of proceeds from equity offerings in the first quarter of 2021 to strengthen the balance sheet; Ascensia Diabetes Care initiated Eversense® sales and marketing activities in Europe in select markets on February 1, 2021; Eversense implantable CGM CPT codes were added to the 2021 Medicare Physician Fee Schedule improving national reimbursement payment availability for implantable CGM systems and physician services; and Reduced fourth quarter operating expenses by $13.8 million, compared to the prior year period, resulting from the execution of strategic cost reductions and the streamlined operational focus.


Neurocrine Biosciences, Inc. (NASDAQ: NBIX) recently announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial Officer of Gilead Sciences, with responsibility for the global commercialization of Gilead’s medicines.


“We are pleased to add Johanna Mercier to the Board of Directors at Neurocrine Biosciences,” said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences. “Johanna is an accomplished commercial leader and her extensive global experience within the biopharmaceutical industry will be invaluable to Neurocrine and our Board of Directors.”


Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, recently announced its operating and financial results for the fourth quarter and full-year 2020.


Recent Highlights: Senhance Surgical System received expanded 510(k) clearance for general surgery indication; Asensus Surgical received CE Mark for Intelligent Surgical Unit™(ISU™), enabling machine vision capabilities in Europe; Performed first pediatric cases utilizing Senhance® Surgical System, representing the first time that 3 mm instruments were used in robotic pediatric surgery; Senhance received its registration certificate by the Russian medical device regulatory agency, Roszdravnadzor, allowing for its sale and utilization throughout the Russian Federation; Announced partnering arrangement with Amsterdam Skills Centre to launch Senhance surgical training center in the Netherlands; and Closed two equity financings, totaling approximately $111 million in gross proceeds in aggregate, extending cash runway into 2024.


Abbott (NYSE: ABT) recently announced it began shipping its BinaxNOW™ COVID-19 Ag Self Test to retailers across the country. Consumers can expect the test to be available in the next few days online and in some stores. Broader nationwide availability is expected in the next two weeks as tests work their way through distribution channels.


The BinaxNOW Self Test initially will be available at CVS Pharmacy, Walgreens and Walmart as part of Abbott’s commitment to get the country’s most studied COVID-19 rapid test to as many Americans as possible. The test, which can be purchased over the counter without a prescription, will then roll out to other major food, drug and mass merchandisers in the weeks ahead.


DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates and, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.   For current services performed FNM has been compensated fory five hundred dollars for news coverage of the current press releases issued by Global WholeHealth Partners Corp by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.


Contact Information:

Media Contact email: – +1(561)325-8757



Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.